Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Christian PittardDirector | abrdn Life Sciences InvestorsHQL | Open-market buy | 25/12/16 | 25/12/18 | 7,923 sh | $16.88 | $133,740.24 | No record |
abrdn Life Sciences InvestorsHQL | Open-market sale | 25/09/19–25/09/22 | 25/09/23 | 48,612 sh2 trades | $14.13avg. | $687,094.12 | −1.7% | |
abrdn Life Sciences InvestorsHQL | Open-market sale | 25/09/17–25/09/18 | 25/09/19 | 64,536 sh2 trades | $14.04avg. | $906,075.28 | −2.2% | |
abrdn Life Sciences InvestorsHQL | Open-market sale | 25/09/15–25/09/16 | 25/09/17 | 2,726 sh2 trades | $14.03avg. | $38,234.74 | −0.1% | |
Saba Capital Management10% Owner | abrdn Life Sciences InvestorsHQL | Open-market sale | 25/09/11 | 25/09/15 | 15,116 sh | $14.28 | $215,856.48 | −0.5% |
Saba Capital Management10% Owner | abrdn Life Sciences InvestorsHQL | Open-market sale | 25/09/02 | 25/09/04 | 14,083 sh | $14.04 | $197,725.32 | −0.5% |
Saba Capital Management10% Owner | abrdn Life Sciences InvestorsHQL | Open-market sale | 25/08/29 | 25/09/02 | 23,723 sh | $13.89 | $329,512.47 | −0.8% |
Saba Capital Management10% Owner | abrdn Life Sciences InvestorsHQL | Open-market sale | 25/08/26 | 25/08/27 | 400 sh | $13.83 | $5,532 | −0.0% |
Saba Capital Management10% Owner | abrdn Life Sciences InvestorsHQL | Open-market sale | 25/08/21 | 25/08/25 | 10,710 sh | $14.07 | $150,689.7 | −0.4% |
Saba Capital Management10% Owner | abrdn Life Sciences InvestorsHQL | Open-market sale | 25/05/20 | 25/05/22 | 11,419 sh | $12.71 | $145,135.49 | −0.4% |
Saba Capital Management10% Owner | abrdn Life Sciences InvestorsHQL | Open-market sale | 25/05/15 | 25/05/19 | 23,729 sh | $12.08 | $286,646.32 | −0.8% |
abrdn Life Sciences InvestorsHQL | Open-market sale | 25/05/13–25/05/14 | 25/05/15 | 1,330 sh2 trades | $12.17avg. | $16,188.4 | −0.0% | |
Saba Capital Management10% Owner | abrdn Life Sciences InvestorsHQL | Open-market sale | 25/05/08 | 25/05/12 | 12,689 sh | $11.98 | $152,014.22 | −0.4% |
Saba Capital Management10% Owner | abrdn Life Sciences InvestorsHQL | Open-market sale | 25/05/07 | 25/05/08 | 1,366 sh | $12.19 | $16,651.54 | −0.0% |
Saba Capital Management10% Owner | abrdn Life Sciences InvestorsHQL | Open-market sale | 25/04/17 | 25/04/21 | 9,144 sh | $11.78 | $107,716.32 | −0.3% |
Saba Capital Management10% Owner | abrdn Life Sciences InvestorsHQL | Open-market sale | 25/04/15 | 25/04/17 | 1,700 sh | $11.92 | $20,264 | −0.1% |
Saba Capital Management10% Owner | abrdn Life Sciences InvestorsHQL | Open-market sale | 25/04/14 | 25/04/15 | 15,400 sh | $11.67 | $179,718 | −0.5% |
Saba Capital Management10% Owner | abrdn Life Sciences InvestorsHQL | Open-market sale | 25/04/10 | 25/04/14 | 30,156 sh | $11.14 | $335,937.84 | −1.0% |
abrdn Life Sciences InvestorsHQL | Open-market sale | 25/04/03–25/04/04 | 25/04/07 | 17,210 sh2 trades | $11.97avg. | $205,931.56 | −0.5% | |
abrdn Life Sciences InvestorsHQL | Open-market sale | 25/04/01–25/04/02 | 25/04/03 | 46,723 sh2 trades | $12.34avg. | $576,754.01 | −1.5% |